Saving lives through accurate diagnosis followed by swift treatment is the major outcome of new and pioneering medical inventions and technologies. And it is encouraging to see that the healthcare industry is heading towards this goal. With this in mind, we have listed three medical advances which have helped to change the medical scenario throughout the world.
The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
Philadelphia-based Carisma Therapeutics bagged $53 million in series A funding, led by AbbVie Ventures Co-led by HealthCap, new backers Wellington Partners, MRL Ventures Fund, TPG Biotech, and Agent Capital.
Scientists from the Melbourne Walter and Eliza Hall Institute and the Howard Hughes Medical Institute (US) have discovered a new vaccine for malaria, revealing an 'atomic-scale' blueprint of how the parasite seize human cells using a new technology called CRYO-EM (cryo-electron microscopy).
A new research collaborative study by Sensorion and UConn Health, presented at the 53rd American Neurotology Society Annual Spring Meeting, revealed the first potential biomarker for noise-induced hearing loss. The research team analyzed blood samples to check the level of serum prestin. The severity of hearing loss would be dependent upon the level of prestin circulated in the blood associated with the changes in an outer hair cell protein.
RET-driven cancers include medullary and papillary thyroid cancer, non-small cell lung cancer, colorectal and bile duct cancer, which have been very difficult to treat till date. Chemotherapy has been the only available treatment but leads to multiple side effects.
To develop small molecules which can target RNA mis-splicing in neurological diseases, Celgene is launching a $60 million collaboration with Skyhawk Therapeutics. Celgene received the option to develop up to five drug molecules for correcting neurological diseases such as Huntington’s disease, amyotrophic lateral sclerosis etc. The $60 million payment includes milestones, license fees and royalties.
The DDF initially aimed to raise £130 million with committed investments from GlaxoSmithKline, Biogen, Eli Lilly, Pfizer and Takeda, Johnson & Johnson, as well as the U.K. government’s Department of Health and the nonprofit Alzheimer’s Research UK.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.